Compounds > dabigatran
Page last updated: 2024-09-05

dabigatran and zd 6474

dabigatran has been researched along with zd 6474 in 1 studies

Compound Research Comparison

Studies
(dabigatran)		Trials
(dabigatran)		Recent Studies (post-2010)
(dabigatran)		Studies
(zd 6474)		Trials
(zd 6474)		Recent Studies (post-2010) (zd 6474)
3,8872613,49062388413

Protein Interaction Comparison

ProteinTaxonomydabigatran (IC50)zd 6474 (IC50)
Tyrosine-protein kinase ABL1Homo sapiens (human)0.1185
Epidermal growth factor receptorHomo sapiens (human)0.5373
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)1.6
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.7738
Platelet-derived growth factor receptor betaHomo sapiens (human)0.7885
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.343
Fibroblast growth factor receptor 1Homo sapiens (human)2.7925
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.0769
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.5812
Kinesin-1 heavy chainHomo sapiens (human)0.4
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.1464
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.5425
Angiopoietin-1 receptorHomo sapiens (human)1.5335
Macrophage-stimulating protein receptorHomo sapiens (human)3.37
Coiled-coil domain-containing protein 6Homo sapiens (human)0.02
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)0.2

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Furberg, CD; Moore, TJ1

Other Studies

1 other study(ies) available for dabigatran and zd 6474

ArticleYear
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
    JAMA, 2012, Sep-05, Volume: 308, Issue:9

    Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Dabigatran; Drug Approval; Efficiency, Organizational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Patient Safety; Piperidines; Propylene Glycols; Quinazolines; Risk; Sphingosine; Stroke; Thyroid Neoplasms; Time Factors; United States; United States Food and Drug Administration

2012